Wedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

Benzinga Newsdesk www.benzinga.com Negative 66.5%

Neg 66.5% Neu 0% Pos 0%

Wedbush analyst Laura Chico reiterates Ovid Therapeutics (NASDAQ:OVID) with a Outperform and maintains $7 price target.

Comments

No comments yet. Be the first!